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Abstract
A non-smoking 77-year old gentleman of Indian origin was admitted with a 4-month history of
intermittent night sweats, haemoptysis and 6 kg of weight loss. CT scan of thorax demonstrated a
2.5 cm mass in the right middle lobe with multiple small nodules within the right lung and confirmed
the presence of mediastinal and hilar lymph nodes.
Fibreoptic bronchoscopy demonstrated a distorted right main bronchus, anterior shift of the right
upper lobe and occlusion of the right middle lobe bronchus with a black necrotic ulcer.
Mycobacterium tuberculosis was found in the bronchoalveolar lavage and histology demonstrated
numerous fungal hyphae with a morphological appearance of zygomycetes within necrotic areas of
tissue. Medical management with anti-fungal and anti-mycobacterial treatment was instigated as the
patient's pre-existing IHD did not permit surgical intervention. Subsequently CT imaging following
completion of therapy demonstrated improvement of the mass and a resolution of the associated
nodules. The patient has been followed for 6 months to date and there has been no recurrence of
symptoms. Recent bronchoalveolar lavage cultures have been negative for M. tuberculosis and
zygomycetes.
Case presentation
A non-smoking 77-year old gentleman of Indian origin
was admitted with a 4-month history of intermittent night
sweats, haemoptysis and 6 kg of weight loss. He had no
past history of Mycobacterium tuberculosis infection but suf-
fered from significant ischaemic heart disease (IHD).
There was no history of diabetes mellitus and random
blood glucose levels were normal. Testing for human
immunodeficiency virus (HIV) was not undertaken as the
patient was not felt to be at risk for HIV infection. Clinical
examination was unremarkable apart from low grade
pyrexia. He was retired and had recently arrived in the
United Kingdom from India.
Routine laboratory investigations were normal apart from
an elevated CRP at 22.1 mg/L. Chest x-ray revealed bilat-
eral hilar lymphadenopathy and a mass in the right lower
zone. CT scan of thorax demonstrated a 2.5 cm mass in
the right middle lobe with multiple small nodules within
the right lung and confirmed the presence of mediastinal
and hilar lymph nodes.
Fibreoptic bronchoscopy demonstrated a distorted right
main bronchus, anterior shift of the right upper lobe and
occlusion of the right middle lobe bronchus with black
necrotic material (See Figure 1). Acid and alcohol fast
bacilli (AAFB) were visible on microscopy in the broncho-
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alveolar lavage (BAL) fluid and were subsequently identi-
fied as M. tuberculosis. Histological examination of
endobronchial biopsies taken from the necrotic material
showed numerous fungal hyphae with a morphological
appearance of zygomycetes within necrotic areas of tissue.
Fungal cultures were negative; therefore anti-fungal sensi-
tivity testing could not be performed.
Medical management was instigated as the patient's pre-
existing IHD did not permit surgical intervention. Intrave-
nous liposomal amphotericin (Ambisome, Gilead) at a
dose of 3 mg/kg and standard four drug anti-mycobacte-
rial regimen consisting of rifampicin, isoniazid, pyrazina-
mide and ethambutol was commenced. Following three
weeks of therapy the intravenous liposomal amphotericin
was changed to oral itraconazole (Sporanox, Janssen-
Cilag) 200 mg once daily, which was increased to 200 mg
twice daily following low therapeutic monitoring. Subse-
quent itraconazole levels were within the therapeutic
range.
The patient completed 6 months of oral anti-fungal treat-
ment. Due to concerns on a follow-up CT scan regarding
lack of resolution of the multiple nodules 18 months of
anti- mycobacterial chemotherapy was administered. Sub-
sequently CT imaging following completion of anti-
mycobacterial chemotherapy demonstrated improvement
of the mass and a resolution of the associated nodules.
The patient has been followed for 6 months to date and
there has been no recurrence of symptoms. Recent BAL
cultures have been negative for M. tuberculosis and zygo-
mycetes.
Conclusion
Zygomycetes are the third most common invasive fungal
infection in humans after Aspergillus sp. and Candida sp.
Inhalation of the spores from the environment is thought
to be the primary mode of transmission of zygomycetes
[1] with the lungs being the second commonest site of
infection [2,3].
Pulmonary zygomycosis is 2 to 3 times more common in
men than women [4,5]and the main risk factors include
diabetes mellitus, haematological malignancy, renal
insufficiency and solid organ transplantation. Pulmonary
zygomycosis has been rarely reported in the absence of
recognised risk factors [6,7]. Up to 32% of patients pre-
senting with zygomycosis have been observed to have a
concurrent infection which is usually bacterial in origin
[4]. In some cases zygomycetes may infect lung cavities
following pulmonary tuberculosis [8]. There is only one
report of pulmonary zygomycosis and M. tuberculosis
infection occurring simultaneously in a patient with acute
myeloid leukaemia [9].
Pulmonary zygomycosis usually presents as a diffuse
pneumonia causing cough, fever and haemoptysis.
Involvement of the mediastinal structures can occur as
does distant haematogenous spread. Chest X-ray typically
shows consolidation or the presence of discrete masses.
Chest CT scans can reveal additional abnormalities and
cavitation in 26% and 40% of cases respectively [10].
Bronchoscopy may be useful in establishing the diagnosis
of zygomycosis via BAL or transbronchial biopsy. The
endobronchial findings of zygomycosis include the pres-
ence of granulation tissue, gelatinous tissue, stenosis and
a necrotic ulcer [11]. Collins et al reviewed the published
cases of endobronchial zygomycosis and found that the
right bronchial tree was more commonly involved, and
postulated the possibility of inhalation or aspiration of
material may be important in the pathogenesis of the con-
dition [11]. Histology is often required to establish the
diagnosis which typically shows non-septated right angle
branching-shaped hyphae [3]. Combined surgical and
medical treatment of zygomycosis has a reported mortal-
ity of 45%, compared to medical treatment alone which
has a mortality of 70–80% [5,10]. Treatment of zygomy-
cosis consists of the prompt instigation of amphotericin
treatment, preferentially combined with surgical resection
of the necrotic tissue. Oral azoles have little activity
against zygomycetes; however there are anecdotal reports
of azoles having some benefit [12-14]. Posaconazole, a
new triazole maybe of some benefit in the treatment of
patients with zygomycosis [15]. The main determinant of
mortality relates to the nature of the underlying disease.
Black necrotic material in right middle lobe bronchus Figure 1
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To our knowledge this is the first report of concurrent pul-
monary zygomycosis and M. tuberculosis infection occur-
ring in a patient with an absence of recognised risk factors.
Despite surgical intervention being precluded due to IHD,
medical therapy has resulted in a cure.
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